Azimuth Capital Investment Management LLC Sells 25,976 Shares of Medtronic PLC $MDT

Key Points

• Azimuth Capital Investment Management cut its Medtronic stake by 25%, selling 25,976 shares in the second quarter and retaining 77,746 shares valued at approximately $6.08 million. Institutional investors collectively own 82.06% of the company.
• Medtronic reported better-than-expected quarterly results, with EPS of $1.45 and revenue of $9.76 billion; revenue rose 13.7% year over year. The company also declared a $0.72 quarterly dividend, equivalent to a 3.1% annual yield.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $103.92 versus the stock’s $94.12 opening price.

Azimuth Capital Investment Management LLC decreased its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 25.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 77,746 shares of the medical technology company's stock after selling 25,976 shares during the period. Azimuth Capital Investment Management LLC's holdings in Medtronic were worth $6,082,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Monetary Solutions Ltd acquired a new stake in Medtronic during the 4th quarter valued at $27,000. Acumen Wealth Advisors LLC acquired a new stake in shares of Medtronic in the fourth quarter valued at $29,000. IAG Wealth Partners LLC acquired a new stake in shares of Medtronic in the second quarter valued at $30,000. Imprint Wealth LLC bought a new position in shares of Medtronic in the third quarter valued at about $31,000. Finally, Basepoint Wealth LLC bought a new position in shares of Medtronic in the fourth quarter valued at about $32,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Stock Down 0.1%

Shares of MDT stock opened at $94.12 on Monday. The firm has a market capitalization of $120.39 billion, a P/E ratio of 23.18, a PEG ratio of 2.21 and a beta of 0.56. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The firm's fifty day moving average price is $86.78 and its two-hundred day moving average price is $85.27.

Medtronic (NYSE:MDT - Get Free Report) last released its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The business had revenue of $9.76 billion during the quarter, compared to analysts' expectations of $9.55 billion. During the same period last year, the business earned $1.26 earnings per share. The firm's revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities analysts predict that Medtronic PLC will post 5.96 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 annualized dividend and a yield of 3.1%. Medtronic's dividend payout ratio (DPR) is 70.94%.

Analysts Set New Price Targets

A number of brokerages have commented on MDT. Truist Financial reiterated a "hold" rating and issued a $99.00 price objective (up from $86.00) on shares of Medtronic in a research report on Wednesday. BTIG Research boosted their target price on Medtronic from $91.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, September 1st. Jefferies Financial Group reaffirmed a "hold" rating and set a $88.00 price target on shares of Medtronic in a research note on Thursday, June 4th. UBS Group raised their price target on Medtronic from $100.00 to $110.00 and gave the company a "buy" rating in a report on Thursday. Finally, Stifel Nicolaus raised their price objective on shares of Medtronic from $80.00 to $95.00 and gave the company a "hold" rating in a research note on Wednesday, September 2nd. Nineteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $103.92.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic said executives will present at the Wells Fargo Healthcare Conference on September 8 and other upcoming investor events. These appearances could provide additional updates on growth initiatives, product launches, and financial guidance. Medtronic executives to speak at upcoming investor conferences
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating, while Stifel Nicolaus, Robert W. Baird, TD Cowen, and BTIG Research maintained bullish assessments or projected meaningful price appreciation. The broad analyst support reinforces investor confidence in MDT’s outlook. Royal Bank of Canada reaffirms Outperform rating
• Positive Sentiment: New real-world evidence from Medtronic’s PERSIST addendum study is supporting the company’s Inceptiv spinal cord stimulation system. Further clinical validation could improve adoption prospects and strengthen the pain-management franchise. Medtronic’s PERSIST study builds real-world evidence
• Positive Sentiment: Medtronic’s latest reported quarter exceeded expectations, with earnings of $1.45 per share versus a $1.39 consensus estimate and revenue of $9.76 billion versus $9.55 billion expected. Revenue increased 13.7% year over year, providing a favorable fundamental backdrop.
• Neutral Sentiment: Unusually large options trading indicates elevated investor interest in MDT, but the activity does not by itself establish whether traders expect further gains or a pullback. Medtronic target of unusually large options trading
• Negative Sentiment: A MarketWatch strategy highlighted Medtronic as a healthcare stock that may be overcrowded, recommending a bearish options position because many investors have already bet on additional gains. This raises the risk of profit-taking or volatility despite the positive fundamental and analyst backdrop. Healthcare stocks may be too crowded to own

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source